334 related articles for article (PubMed ID: 27190342)
21. Combined angiotensin-converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients.
Chan KE; Ikizler TA; Gamboa JL; Yu C; Hakim RM; Brown NJ
Kidney Int; 2011 Nov; 80(9):978-985. PubMed ID: 21775975
[TBL] [Abstract][Full Text] [Related]
22. Stopping renin-angiotensin system blockers after acute kidney injury and risk of adverse outcomes: parallel population-based cohort studies in English and Swedish routine care.
Bidulka P; Fu EL; Leyrat C; Kalogirou F; McAllister KSL; Kingdon EJ; Mansfield KE; Iwagami M; Smeeth L; Clase CM; Bhaskaran K; van Diepen M; Carrero JJ; Nitsch D; Tomlinson LA
BMC Med; 2020 Jul; 18(1):195. PubMed ID: 32723383
[TBL] [Abstract][Full Text] [Related]
23. Incidence of and Risk Factors for Severe Adverse Events in Elderly Patients Taking Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers after an Acute Myocardial Infarction.
Fang G; Annis IE; Farley JF; Mahendraratnam N; Hickson RP; Stürmer T; Robinson JG
Pharmacotherapy; 2018 Jan; 38(1):29-41. PubMed ID: 29059475
[TBL] [Abstract][Full Text] [Related]
24. Angiotensin Receptor Blockers as an Alternative to Angiotensin-Converting Enzyme Inhibitors in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention.
Lim S; Choo EH; Choi IJ; Ihm SH; Kim HY; Ahn Y; Chang K; Jeong MH; Seung KB
J Korean Med Sci; 2019 Nov; 34(45):e289. PubMed ID: 31760711
[TBL] [Abstract][Full Text] [Related]
25. Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Myocardial Infarction Patients With Renal Dysfunction.
Evans M; Carrero JJ; Szummer K; Åkerblom A; Edfors R; Spaak J; Jacobson SH; Andell P; Lindhagen L; Jernberg T
J Am Coll Cardiol; 2016 Apr; 67(14):1687-97. PubMed ID: 27056774
[TBL] [Abstract][Full Text] [Related]
26. Risk of Mild Cognitive Impairment or Probable Dementia in New Users of Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors: A Secondary Analysis of Data From the Systolic Blood Pressure Intervention Trial (SPRINT).
Cohen JB; Marcum ZA; Zhang C; Derington CG; Greene TH; Ghazi L; Herrick JS; King JB; Cheung AK; Bryan N; Supiano MA; Sonnen JA; Weintraub WS; Scharfstein D; Williamson J; Pajewski NM; Bress AP;
JAMA Netw Open; 2022 Jul; 5(7):e2220680. PubMed ID: 35834254
[TBL] [Abstract][Full Text] [Related]
27. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high vascular risk.
Potier L; Roussel R; Elbez Y; Marre M; Zeymer U; Reid CM; Ohman M; Eagle KA; Bhatt DL; Steg PG;
Heart; 2017 Sep; 103(17):1339-1346. PubMed ID: 28285267
[TBL] [Abstract][Full Text] [Related]
28. Comparative Effectiveness of Angiotensin II Receptor Blockers Versus Angiotensin-Converting Enzyme Inhibitors Following Contemporary Treatments in Patients with Acute Myocardial Infarction: Results from the Korean Working Group in Myocardial Infarction (KorMI) Registry.
Song PS; Seol SH; Seo GW; Kim DK; Kim KH; Yang JH; Hahn JY; Gwon HC; Ahn Y; Jeong MH; Song YB; Kim DI;
Am J Cardiovasc Drugs; 2015 Dec; 15(6):439-49. PubMed ID: 26153396
[TBL] [Abstract][Full Text] [Related]
29. Comparative Effectiveness of Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors in Older Nursing Home Residents After Myocardial Infarction: A Retrospective Cohort Study.
Zullo AR; Riester MR; Erqou S; Wu WC; Rudolph JL; Steinman MA
Drugs Aging; 2020 Oct; 37(10):755-766. PubMed ID: 32808250
[TBL] [Abstract][Full Text] [Related]
30. Cardiovascular and kidney outcomes of spironolactone or eplerenone in combination with ACEI/ARBs in patients with diabetic kidney disease.
An J; Niu F; Sim JJ
Pharmacotherapy; 2021 Dec; 41(12):998-1008. PubMed ID: 34655484
[TBL] [Abstract][Full Text] [Related]
31. CAC score as a possible criterion for administration of angiotensin converting enzyme inhibitors and/or angiotensin receptor blockers: the MultiEthnic Study of Atherosclerosis.
Darabian S; Luo Y; Homat A; Khosraviani K; Wong N; Zeb I; Nasir K; Budoff MJ
Coron Artery Dis; 2015 Dec; 26(8):678-85. PubMed ID: 26398149
[TBL] [Abstract][Full Text] [Related]
32. Effects of withdrawing vs continuing renin-angiotensin blockers on incidence of acute kidney injury in patients with renal insufficiency undergoing cardiac catheterization: Results from the Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker and Contrast Induced Nephropathy in Patients Receiving Cardiac Catheterization (CAPTAIN) trial.
Bainey KR; Rahim S; Etherington K; Rokoss ML; Natarajan MK; Velianou JL; Brons S; Mehta SR;
Am Heart J; 2015 Jul; 170(1):110-6. PubMed ID: 26093871
[TBL] [Abstract][Full Text] [Related]
33. ARNI versus ACEI/ARB in Reducing Cardiovascular Outcomes after Myocardial Infarction.
She J; Lou B; Liu H; Zhou B; Jiang GT; Luo Y; Wu H; Wang C; Yuan Z
ESC Heart Fail; 2021 Dec; 8(6):4607-4616. PubMed ID: 34664407
[TBL] [Abstract][Full Text] [Related]
34. Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With Outcomes After Acute Kidney Injury.
Brar S; Ye F; James MT; Hemmelgarn B; Klarenbach S; Pannu N;
JAMA Intern Med; 2018 Dec; 178(12):1681-1690. PubMed ID: 30422153
[TBL] [Abstract][Full Text] [Related]
35. Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use is associated with reduced major adverse cardiovascular events among patients with critical limb ischemia.
Armstrong EJ; Chen DC; Singh GD; Amsterdam EA; Laird JR
Vasc Med; 2015 Jun; 20(3):237-44. PubMed ID: 25835349
[TBL] [Abstract][Full Text] [Related]
36. Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on major adverse cardiac events in patients with newly diagnosed type 2 diabetes: a nationwide study.
Shih CJ; Chu H; Ou SM; Chen YT
Int J Cardiol; 2015 Nov; 199():283-9. PubMed ID: 26218587
[TBL] [Abstract][Full Text] [Related]
37. Longer Predialysis ACEi/ARB Utilization Is Associated With Reduced Postdialysis Mortality.
Gosmanova EO; Molnar MZ; Naseer A; Sumida K; Potukuchi P; Gaipov A; Wall BM; Thomas F; Streja E; Kalantar-Zadeh K; Kovesdy CP
Am J Med; 2020 Sep; 133(9):1065-1073.e3. PubMed ID: 32330490
[TBL] [Abstract][Full Text] [Related]
38. Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses.
Catalá-López F; Macías Saint-Gerons D; González-Bermejo D; Rosano GM; Davis BR; Ridao M; Zaragoza A; Montero-Corominas D; Tobías A; de la Fuente-Honrubia C; Tabarés-Seisdedos R; Hutton B
PLoS Med; 2016 Mar; 13(3):e1001971. PubMed ID: 26954482
[TBL] [Abstract][Full Text] [Related]
39. Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, β-blockers or both in incident end-stage renal disease patients without cardiovascular disease: a propensity-matched longitudinal cohort study.
Ferreira JP; Couchoud C; Gregson J; Tiple A; Glowacki F; London G; Agarwal R; Rossignol P
Nephrol Dial Transplant; 2019 Jul; 34(7):1216-1222. PubMed ID: 30590716
[TBL] [Abstract][Full Text] [Related]
40. Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chemoprevention of hepatocellular carcinoma: a nationwide high-risk cohort study.
Ho CM; Lee CH; Lee MC; Zhang JF; Wang JY; Hu RH; Lee PH
BMC Cancer; 2018 Apr; 18(1):401. PubMed ID: 29631561
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
